share_log

CannMart Marks International Debut With First Shipment of Cannabis Products to Australia

CannMart Marks International Debut With First Shipment of Cannabis Products to Australia

CannMart 首次向澳大利亞運送大麻產品,標誌着國際首次亮相
GlobeNewswire ·  04/15 19:00

TORONTO, April 15, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, today announced that its subsidiary CannMart Inc. ("CannMart") has made a landmark shipment of premium cannabis products to Australia, including vape carts plus two extracts from its own Roilty brand. In December 2023 CannMart announced its intention to begin exporting cannabis products to Australia, through an agreement with Aura Therapeutics Pty Ltd. ("Aura") to include concentrate and vape carts, bulk flower, and other refined concentrate products in the quickly developing Australian medical cannabis industry. This milestone shipment represents a significant achievement for CannMart, as it expands its presence beyond Canadian borders and enters the large and growing Australian medical cannabis market.

多倫多,2024年4月15日(環球新聞專線)——利用科學和技術進步建立改變人類健康的突破性企業的健康科技公司Lifeist Wellness Inc.(“Lifeist” 或 “公司”)(多倫多證券交易所股票代碼:LFST)(法蘭克福股票代碼:M5B)(OTCMKTS:LFSWF)今天宣佈,其子公司CannMart Inc.(“CannMart”)向澳大利亞運送了具有里程碑意義的優質大麻產品,包括電子煙車和自有Roilty品牌的兩種提取物。2023年12月,CannMart宣佈打算通過與Aura Therapeutics Pty Ltd.(“Aura”)達成協議,開始向澳大利亞出口大麻產品,將濃縮物和電子煙車、散裝花和其他精製濃縮產品納入快速發展的澳大利亞醫用大麻行業。這批具有里程碑意義的出貨代表了CannMart的一項重大成就,因爲它將其業務擴展到了加拿大境外,並進入了龐大且不斷增長的澳大利亞醫用大麻市場。

"The export of cannabis products to Australia underscores CannMart's commitment to expanding its footprint beyond Canadian borders and catering to the evolving needs of medical cannabis patients worldwide," said Daniel Stern, CEO of CannMart. "These high-margin products are poised to make a significant impact in the Australian medical cannabis market, which continues to experience substantial growth and demand for quality cannabis products. The launch of our own Roilty products in Australia also marks a significant milestone in our international expansion strategy."

CannMart首席執行官丹尼爾·斯特恩表示:“向澳大利亞出口大麻產品凸顯了CannMart致力於將其足跡擴展到加拿大境外,並滿足全球醫用大麻患者不斷變化的需求。”“這些高利潤產品有望對澳大利亞醫用大麻市場產生重大影響,該市場繼續保持大幅增長,對優質大麻產品的需求也很高。我們在澳大利亞推出自己的Roilty產品也標誌着我們國際擴張戰略的重要里程碑。”

Australia boasts a large and growing medical cannabis market, with increasing demand for high-quality cannabis products to address various medical conditions. By entering this market, CannMart aims to meet the needs of Australian patients and contribute to the advancement of medical cannabis access and awareness.

澳大利亞擁有龐大且不斷增長的醫用大麻市場,對解決各種疾病的高質量大麻產品的需求不斷增加。通過進入這個市場,CannMart旨在滿足澳大利亞患者的需求,爲提高醫用大麻的可及性和認識做出貢獻。

One of the foremost advantages of exporting CannMart products to Australia is the absence of Canadian excise taxes on export products. This allows CannMart to offer its high-margin cannabis products at competitive prices, further enhancing its appeal to Australian consumers.

向澳大利亞出口CannMart產品的最大優勢之一是加拿大不對出口產品徵收消費稅。這使CannMart能夠以具有競爭力的價格提供其高利潤的大麻產品,進一步增強了其對澳大利亞消費者的吸引力。

CannMart products are meticulously crafted to meet stringent quality standards, ensuring consistency efficacy for patients seeking relief from various medical conditions. The Roilty brand is known for its exceptional quality and potency, making it a preferred choice among discerning cannabis consumers in Canada and now in Australia. With its inaugural launch in Australia, CannMart and its brand Roilty are poised to capture the attention of medical cannabis patients seeking premium-grade products for therapeutic use in other global markets.

CannMart 產品經過精心製作,符合嚴格的質量標準,可確保尋求緩解各種疾病的患者獲得一致的療效。Roilty品牌以其卓越的品質和效力而聞名,使其成爲加拿大和現在澳大利亞挑剔的大麻消費者的首選。隨着在澳大利亞的首次推出,CannMart及其品牌Roilty有望吸引在其他全球市場尋求優質治療用途產品的醫用大麻患者的注意。

CannMart remains committed to upholding the highest standards of quality, safety, and efficacy in its cannabis products, ensuring that patients have access to reliable and effective treatment options. As the global cannabis market continues to evolve, CannMart is dedicated to exploring new opportunities for growth and innovation, while remaining steadfast in its mission to improve the well-being of individuals worldwide.

CannMart仍然致力於維護其大麻產品的最高質量、安全性和有效性標準,確保患者獲得可靠和有效的治療選擇。隨着全球大麻市場的持續發展,CannMart致力於探索新的增長和創新的機會,同時堅定不移地履行其改善全球個人福祉的使命。

About Lifeist Wellness Inc.

關於 Lifeist Wellness

Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include: Mikra, a biosciences and consumer wellness company developing and selling innovative products for cellular health; CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards including for CannMart Labs, a BHO extraction facility producing high margin cannabis 2.0 products; and Australian Vapes, one of Australia's largest online retailers of vaporizers and accessories.

Lifeist處於疫情後健康革命的最前沿,利用科學和技術的進步來建立突破性公司,改變人類健康。投資組合業務部門包括:開發和銷售細胞健康創新產品的生物科學和消費者健康公司Mikra;CannMart,該公司經營B2B批發分銷業務,促進向加拿大省政府控制委員會銷售休閒大麻,包括生產高利潤大麻2.0產品的BHO提取設施CannMart Labs;以及澳大利亞最大的蒸發器和配件在線零售商之一澳大利亞Vapes。

Information on Lifeist and its businesses can be accessed through the links below:

有關Lifeist及其業務的信息可以通過以下鏈接訪問:

Contact:
Meni Morim
CEO
Lifeist Wellness Inc.
Ph: 647-362-0390
Email: ir@lifeist.com

聯繫人:
Meni Morim
首席執行官
Lifeist健康公司
Ph:647-362-0390
電子郵件:ir@lifeist.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險投資交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任,也未以任何方式批准或不批准本新聞稿的內容。

Forward Looking Information

前瞻性信息

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as "may", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen.

本新聞稿包含適用證券法所指的 “前瞻性信息”。此處包含的所有非歷史性陳述均包含前瞻性信息。前瞻性信息可以通過單詞或短語來識別,例如 “可能”、“期望”、“可能”、“應該”、“將”、“計劃”、“預期”、“打算”、“潛在”、“提議”、“估計”、“相信” 或這些術語的否定詞、表達方式和語法變體,或某些事件或條件 “可能” 或 “將” 發生的陳述。

The forward-looking information contained herein, including, without limitation, statements related to the expected impact of CannMart's products in the Australian medical cannabis market and general expectations relating to the Company's international expansion strategy, are based on assumptions management believed to be reasonable at the time such statements were made, including without limitation, that the Australian medical cannabis industry will develop as anticipated, expectations relating to anticipated sales of CannMart's products, including Roilty in particular, expectations that Roilty will gain market acceptance, as well as other considerations that are believed to be appropriate in the circumstances are made as of the date of this news release and is based on assumptions management believed to be reasonable at the time such statements were made. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.

此處包含的前瞻性信息,包括但不限於與CannMart產品對澳大利亞醫用大麻市場的預期影響相關的陳述以及與公司國際擴張戰略相關的總體預期,均基於管理層在發表此類聲明時認爲合理的假設,包括但不限於澳大利亞醫用大麻行業將按預期發展截至本新聞發佈之日,基於管理層在發表此類聲明時管理層認爲合理的假設,對CannMart產品的預期銷售,尤其是Roilty獲得市場認可的預期,以及其他被認爲適合具體情況的考慮因素,得出的。儘管根據管理層目前獲得的信息,我們認爲這些假設是合理的,但無法保證此類預期會被證明是正確的。

By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. Such factors include, without limitation: the growth and demand for quality cannabis products in Australia not being as anticipated, the failure of CannMart's premium cannabis products to gain market acceptance as anticipated, the Australian medical cannabis market's failure to continue to develop and grow, in a timely manner, if at all, the Company's failure to develop its Cannabis business in Australia as anticipated and to realize on the anticipated benefits therefrom, unanticipated changes to current regulations that would adversely impact its business in Australia, and risks relating to the Company's ability to execute its business strategy and the benefits realizable therefrom. Additional risk factors can also be found in the Company's current MD&A filed under the Company's SEDAR+ profile at . Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

就其性質而言,前瞻性信息受固有的風險和不確定性的影響,這些風險和不確定性可能是一般性的,也可能是具體的,這些風險和不確定性可能導致預期、預測、預測、預測或結論不準確,假設可能不正確,目標、戰略目標和優先事項無法實現。各種因素,包括已知和未知的風險,其中許多是我們無法控制的,可能導致實際業績與本新聞稿中的前瞻性信息存在重大差異。這些因素包括但不限於:澳大利亞對優質大麻產品的增長和需求不如預期,CannMart的優質大麻產品未能如預期的那樣獲得市場認可,澳大利亞醫用大麻市場未能繼續及時(如果有的話)發展和增長,該公司未能按預期在澳大利亞發展其大麻業務並從中實現預期的好處,對現行法規的意外變化將對其產生不利影響業務在澳大利亞,以及與公司執行業務戰略的能力及其可帶來的收益相關的風險。其他風險因素還可以在公司SEDAR+簡介下提交的公司當前的MD&A中找到,網址爲。提醒讀者不要過分依賴前瞻性信息。除非適用法律要求,否則公司沒有義務更新或修改任何前瞻性信息,無論是由於新信息、未來事件還是其他原因。本新聞稿中包含的前瞻性陳述受本警示聲明的明確限制。

Source: Lifeist Wellness Inc.

資料來源:Lifeist Wellness


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論